Most of the umbilical cord blood collected at birth is discarded. The tissue is clamped, cut, and disposed of as medical waste, along with the stem cells it contains, cells that are immunologically naive, genetically diverse, and capable of being repro…
The Munich techbio company is developing a live bacterial product designed to enhance immune checkpoint inhibitor response in advanced melanoma, with a Phase 1B study planned for 2027 mbiomics GmbH, a Munich-based techbio company developing microbiome-…
3TS Capital Partners led the round with Grazia Equity and existing investors. 25,000 users, 85% daily wear rate, 500,000+ emergency calls handled. The company is building an AI companion for the watch to address loneliness in the hours when no family m…
Claim Clarity suggests that workers’ compensation represents a significant yet often less visible segment of the broader healthcare ecosystem. Founder and CEO Jamie LaPaglia says, “Its scale and impact continue to expand, but it’s sometimes approached …
Medical alert systems have become an essential safety tool for older adults who want to maintain their independence while ensuring help is available at the press of a button. These devices connect users to trained emergency operators 24/7, providing pe…
The New York startup has built AI that reads handwritten fax forms, processes prior authorisations, and completes patient intakes in under five minutes, all without asking providers to change how they work. It has reached multiple millions in revenue i…
The Eindhoven neurotechnology company is using the proceeds to fund its Empower BP pivotal trial, which tests whether its implantable ARC-IM® system can treat blood pressure instability after spinal cord injury, while expanding commercial rollout of it…
The European Investment Bank is lending €20 million to BioLamina, the Swedish biotech that supplies the laminin-based cell culture matrices used by stem cell therapy developers worldwide. The funding will support expanded production of laminin technolo…
STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by existing investors including Pfizer Ventures and M Vent…
Amazon Web Services (AWS) announced this Tuesday the launch of its AI bio tool, Amazon Bio Discovery, to accelerate the early-stage process of drug discovery in the pharmaceutical industry. The application aims to help scientists design and test novel…